MCID: INS002
MIFTS: 60

in Situ Carcinoma

Categories: Cancer diseases, Eye diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for in Situ Carcinoma

MalaCards integrated aliases for in Situ Carcinoma:

Name: in Situ Carcinoma 12 15
Carcinoma in Situ 45 74

Classifications:



External Ids:

Disease Ontology 12 DOID:8719
MeSH 45 D002278
NCIt 51 C2917
SNOMED-CT 69 68956006
ICD10 34 D09.9
UMLS 74 C0007099

Summaries for in Situ Carcinoma

Disease Ontology : 12 A carcinoma that is an early development defined by the absence of invasion of surrounding tissues.

MalaCards based summary : in Situ Carcinoma, also known as carcinoma in situ, is related to comedo carcinoma and lobular neoplasia. An important gene associated with in Situ Carcinoma is ESR1 (Estrogen Receptor 1), and among its related pathways/superpathways are Gene Expression and Circadian entrainment. The drugs Aluminum hydroxide and Docetaxel have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and cervix, and related phenotypes are cellular and homeostasis/metabolism

Wikipedia : 77 Carcinoma in situ (CIS) is a group of abnormal cells. While they are a form of neoplasm, there is... more...

Related Diseases for in Situ Carcinoma

Diseases in the Lip Cancer family:

Pre-Malignant Neoplasm Lip Carcinoma in Situ
in Situ Carcinoma Eye Carcinoma in Situ

Diseases related to in Situ Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 410)
# Related Disease Score Top Affiliating Genes
1 comedo carcinoma 33.7 ERBB2 ESR1
2 lobular neoplasia 33.2 BRCA1 CDH1 ERBB2 ESR1
3 endometrium carcinoma in situ 33.2 PGR TP53
4 ductal carcinoma in situ 32.4 BRCA1 CDH1 EGFR ERBB2 ESR1 KRT14
5 cervix uteri carcinoma in situ 32.0 CDKN2A KRT17 SERPIND1 TP53
6 breast carcinoma in situ 31.7 BRCA1 EGFR ERBB2 ESR1 KRT5 PGR
7 vulva cancer 31.5 CDKN2A EGFR TP53
8 cervical cancer 31.2 CDH1 CDKN2A ERBB2 KRT14 KRT5 TP53
9 uterus carcinoma in situ 30.9 CDKN2A KRT17 SERPIND1 TP53
10 breast fibroadenoma 30.3 ERBB2 ESR1 KRT14 PGR
11 pleomorphic adenoma carcinoma 30.2 ERBB2 TP53
12 endometrial squamous cell carcinoma 30.1 CDKN2A ESR1 PGR
13 breast ductal carcinoma 30.0 BRCA1 CDH1 EGFR ERBB2 ESR1 PGR
14 transitional cell carcinoma 29.9 CDH1 CDKN2A EGFR ERBB2 TP53
15 carcinosarcoma 29.9 ERBB2 PGR TP53
16 mammary paget's disease 29.9 EGFR ERBB2 ESR1 PGR
17 bladder cancer 29.9 CDH1 CDKN2A EGFR ERBB2 TP53
18 larynx cancer 29.9 CDKN2A EGFR TP53
19 apocrine adenocarcinoma 29.9 ERBB2 ESR1 KRT5 PGR
20 papillary carcinoma 29.8 CDH1 ERBB2 PGR
21 intrahepatic cholangiocarcinoma 29.8 CDH1 EGFR TP53
22 small cell carcinoma 29.8 CDKN2A EGFR TP53
23 breast disease 29.8 BRCA1 ERBB2 ESR1 KRT5 PGR TP53
24 actinic keratosis 29.8 CDKN2A KRT17 TP53
25 adenosquamous carcinoma 29.7 EGFR KRT5 TP53
26 bilateral breast cancer 29.6 BRCA1 ERBB2 PGR
27 ovarian cancer 1 29.6 BRCA1 CDH1 ERBB2 TP53
28 cervical squamous cell carcinoma 29.5 CDH1 CDKN2A TP53
29 microglandular adenosis 29.4 EGFR ERBB2 PGR TP53
30 fallopian tube carcinoma 29.4 BRCA1 ERBB2 ESR1 PGR TP53
31 female breast cancer 29.4 BRCA1 ERBB2 ESR1 PGR TP53
32 gallbladder cancer 29.3 CDH1 CDKN2A EGFR ERBB2 TP53
33 vulva squamous cell carcinoma 29.3 CDKN2A KRT17 TP53
34 squamous cell carcinoma 29.3 CDH1 CDKN2A EGFR ERBB2 TP53
35 adenocarcinoma 29.3 CDH1 CDKN2A EGFR ERBB2 TP53
36 cholangiocarcinoma 29.2 CDH1 CDKN2A EGFR ERBB2 TP53
37 nasopharyngeal carcinoma 29.2 CDH1 CDKN2A EGFR TP53
38 papilloma 29.2 CDKN2A KRT14 KRT5 TP53
39 lynch syndrome 29.0 BRCA1 CDKN2A EGFR TP53
40 pleomorphic adenoma 28.9 ERBB2 KRT14 TP53
41 ovarian cancer 28.8 BRCA1 CDH1 EGFR ERBB2 ESR1 PGR
42 gastric adenocarcinoma 28.8 CDH1 CDKN2A EGFR ERBB2 TP53
43 pancreatic cancer 28.7 BRCA1 CDH1 CDKN2A EGFR ERBB2 TP53
44 endometrial cancer 28.4 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
45 basaloid squamous cell carcinoma 28.3 CDKN2A EGFR KRT14 KRT17 TP53
46 breast cancer 27.9 BRCA1 CDH1 EGFR ERBB2 ESR1 KIAA0100
47 breast apocrine carcinoma in situ 12.5
48 oral cavity carcinoma in situ 11.7
49 nasal cavity carcinoma in situ 11.7
50 prostate carcinoma in situ 11.7

Graphical network of the top 20 diseases related to in Situ Carcinoma:



Diseases related to in Situ Carcinoma

Symptoms & Phenotypes for in Situ Carcinoma

MGI Mouse Phenotypes related to in Situ Carcinoma:

47 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.47 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
2 homeostasis/metabolism MP:0005376 10.43 AGTR1 BRCA1 CDH1 CDKN2A EGFR ERBB2
3 cardiovascular system MP:0005385 10.41 AGTR1 BRCA1 CDH1 CDKN2A EGFR ERBB2
4 digestive/alimentary MP:0005381 10.39 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
5 growth/size/body region MP:0005378 10.39 AGTR1 BRCA1 CDH1 CDKN2A EGFR ERBB2
6 mortality/aging MP:0010768 10.39 AGTR1 BRCA1 CDH1 CDKN2A EGFR ERBB2
7 endocrine/exocrine gland MP:0005379 10.34 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
8 integument MP:0010771 10.34 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
9 immune system MP:0005387 10.32 AGTR1 BRCA1 CDH1 CDKN2A EGFR ESR1
10 hematopoietic system MP:0005397 10.31 AGTR1 BRCA1 CDKN2A EGFR ESR1 KRT14
11 behavior/neurological MP:0005386 10.3 AGTR1 BRCA1 CDKN2A ERBB2 ESR1 ITGB4
12 embryo MP:0005380 10.22 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
13 adipose tissue MP:0005375 10.16 AGTR1 BRCA1 EGFR ESR1 KRT14 NR3C1
14 craniofacial MP:0005382 10.13 EGFR ERBB2 ITGB4 KRT14 KRT17 KRT5
15 muscle MP:0005369 10.09 BRCA1 CDKN2A EGFR ERBB2 ESR1 NR3C1
16 neoplasm MP:0002006 10.06 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
17 limbs/digits/tail MP:0005371 10.02 BRCA1 EGFR ERBB2 ESR1 KRT5 PGR
18 no phenotypic analysis MP:0003012 10.02 CDH1 CDKN2A EGFR ESR1 KRT17 KRT5
19 normal MP:0002873 9.92 BRCA1 CDH1 EGFR ERBB2 ESR1 NR3C1
20 renal/urinary system MP:0005367 9.81 AGTR1 BRCA1 EGFR ESR1 FKBP4 ITGB4
21 pigmentation MP:0001186 9.73 BRCA1 CDKN2A EGFR KRT14 KRT17 TP53
22 reproductive system MP:0005389 9.7 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
23 respiratory system MP:0005388 9.28 BRCA1 CDKN2A EGFR ERBB2 ESR1 ITGB4

Drugs & Therapeutics for in Situ Carcinoma

Drugs for in Situ Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 422)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3 21645-51-2
2
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2 114977-28-5 148124
3
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
4
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
5
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 10540-29-1 2733526
6
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2 120511-73-1 2187
7
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68-04-2
8
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 51-43-4 5816
9
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 329-65-7 838
10
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
11
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2 107868-30-4 60198
12
Toremifene Approved, Investigational Phase 4,Phase 3,Phase 2 89778-26-7 3005573
13
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 112809-51-5 3902
14
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 77-92-9 311
15
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
16 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Monophosphoryl lipid A Phase 4
19 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
21 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 interferons Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Mitomycins Phase 4,Phase 3,Phase 2,Not Applicable
25 Interferon-alpha Phase 4,Phase 3,Phase 1,Phase 2
26 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
28 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
33 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1
35 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Selective Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Citrate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Estrogen Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Bronchodilator Agents Phase 4,Phase 2
49 Adrenergic Agents Phase 4,Phase 2
50 Respiratory System Agents Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 763)
# Name Status NCT ID Phase Drugs
1 FASTER-Tlalpan Study Unknown status NCT03105856 Phase 4
2 Can Alternative Treatment Have an Impact on Cervical Dysplasia? Unknown status NCT00842738 Phase 4
3 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Completed NCT01448447 Phase 4
4 Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer Completed NCT00742222 Phase 4
5 Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip Completed NCT00868088 Phase 4
6 Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization Completed NCT02368054 Phase 4 Bupivacaine;Adrenaline
7 Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia Completed NCT02199327 Phase 4 Mitomycin C;Interferon Alfa-2b
8 Management of Cervical Intraepithelial Neoplasia Grade 2 Completed NCT00733109 Phase 4
9 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4
10 Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease Completed NCT01034358 Phase 4
11 Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery Recruiting NCT02627248 Phase 4 Huaier Granule;Epirubicin;Docetaxel;Cyclophosphamide
12 Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study Recruiting NCT03629886 Phase 4
13 HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions Recruiting NCT03051516 Phase 4
14 HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN) Active, not recruiting NCT02087384 Phase 4 Placebo
15 The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) Active, not recruiting NCT02629510 Phase 4 Tachosil
16 Effectiveness of Cervical Screening in HPV Vaccinated Women Enrolling by invitation NCT02149030 Phase 4
17 Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer Withdrawn NCT03238703 Phase 4 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate;Toremifene Citrate
18 Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer Unknown status NCT01094964 Phase 3 epirubicin hydrochloride;mitomycin C
19 Topical Imiquimod for Bowen's Disease of the Head and Neck Unknown status NCT00384124 Phase 2, Phase 3 Imiquimod
20 Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study Unknown status NCT01509781 Phase 3
21 Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing Coordinator Unknown status NCT00321048 Phase 3
22 Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV) Unknown status NCT01095198 Phase 2, Phase 3
23 Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG) Completed NCT01316874 Phase 2, Phase 3 Valrubicin, 800 mg
24 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
25 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
26 Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer Completed NCT00052637 Phase 3 hexaminolevulinate
27 Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Completed NCT02130323 Phase 2, Phase 3 Imiquimod
28 Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions Completed NCT00262899 Phase 3
29 Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ Completed NCT00438659 Phase 3 mometasone furoate
30 Intraoperative Gamma Camera for Breast Cancer Surgery Completed NCT00757302 Phase 3
31 Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer Completed NCT01442519 Phase 3 electromotive mitomycin
32 Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
33 Biological Therapy in Treating Patients With Bladder Cancer Completed NCT00003779 Phase 3
34 Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer Completed NCT00021255 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Herceptin;Carboplatin
35 Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer Completed NCT00006034 Phase 3 doxorubicin hydrochloride
36 Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer Completed NCT00406068 Phase 2, Phase 3 Mycobacterial cell wall-DNA complex
37 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
38 Study of Docetaxel in Breast Cancer Patients Completed NCT00174707 Phase 3 epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, cyclophosphamide
39 A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting Completed NCT02560584 Phase 3 Hexaminolevulinate hydrochloride
40 Surgery and BCG in Treating Patients With Bladder Cancer Completed NCT00002990 Phase 3
41 Docetaxel in Node Positive Adjuvant Breast Cancer Completed NCT00688740 Phase 3 Docetaxel;5-fluorouracil;Doxorubicin;Cyclophosphamide
42 Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer Completed NCT00374322 Phase 3 lapatinib
43 Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer Completed NCT00038467 Phase 3 Tamoxifen;Exemestane
44 Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial Completed NCT02181101 Phase 3 FEC-DocGemzar adjuvant chemotherapy;FEC-Doc adjuvant chemotherapy;Zoledronic acid i.v. 2 years;Zoledronic acid i.v. 5 years
45 Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer Completed NCT00336791 Phase 3 5-Fluorouracil;Cyclophosphamide;Doxorubicin;Paclitaxel;Epirubicin
46 Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer Completed NCT00003771 Phase 3 norethindrone acetate
47 A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study Completed NCT03355820 Phase 3
48 Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS) Completed NCT01131312 Phase 3
49 Efficacy Study of Diathermy Cone Biopsy for the Treatment of Cervical Intraepithelial Lesion Completed NCT00995020 Phase 3
50 Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women Completed NCT00337818 Phase 3

Search NIH Clinical Center for in Situ Carcinoma

Cochrane evidence based reviews: carcinoma in situ

Genetic Tests for in Situ Carcinoma

Anatomical Context for in Situ Carcinoma

MalaCards organs/tissues related to in Situ Carcinoma:

42
Breast, Testes, Cervix, Lymph Node, Prostate, Skin, Testis

Publications for in Situ Carcinoma

Articles related to in Situ Carcinoma:

(show top 50) (show all 3568)
# Title Authors Year
1
Occurrence of newly discovered human polyomaviruses in skin of liver transplant recipients and their relation with squamous cell carcinoma in situ and actinic keratosis - a single-center cohort study. ( 30632206 )
2019
2
Long term oncologic outcome in patients with bladder cancer after radical cystectomy: Impact of carcinoma in situ in the era of neoadjuvant chemotherapy. ( 30706249 )
2019
3
"Development and validation of algorithms to differentiate ductal carcinoma in situ from invasive breast cancer within administrative claims data" by Hirth JM, Hatch SS, Lin Y, Giordano SH, Silva HC, Kuo Y. ( 30875106 )
2019
4
PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer. ( 30844755 )
2019
5
Influence of ductal carcinoma in situ on the outcome of invasive breast cancer. A prospective cohort study. ( 30738200 )
2019
6
Parity Differently Affects the Breast Cancer Specific Survival from Ductal Carcinoma In Situ to Invasive Cancer: A Registry-Based Retrospective Study from Korea. ( 30728717 )
2019
7
Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer in the Carolina Breast Cancer Study. ( 30682163 )
2019
8
Sentinel lymph node biopsy in patients affected by breast ductal carcinoma in situ with and without microinvasion: Retrospective observational study. ( 30608397 )
2019
9
Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment. ( 30653209 )
2019
10
MNK1/NODAL signaling promotes invasive progression of breast ductal carcinoma in situ. ( 30659022 )
2019
11
Identification of aberrant gene expression during breast ductal carcinoma in situ progression to invasive ductal carcinoma. ( 30712460 )
2019
12
The prognostic significance of lysosomal protective protein (Cathepsin A) in breast ductal carcinoma in situ. ( 30725481 )
2019
13
Evaluating the frequency of upgrade to malignancy following surgical excision of high-risk breast lesions and ductal carcinoma in situ identified by core needle biopsy. ( 30461129 )
2019
14
Breast conserving surgery with targeted intraoperative radiotherapy for the management of ductal carcinoma in situ. ( 30589080 )
2019
15
No Ink on Ductal Carcinoma In Situ: A Single Centre Experience. ( 30591495 )
2019
16
National consensus recommendations on patient-centered care for ductal carcinoma in situ. ( 30627960 )
2019
17
BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ. ( 30652428 )
2019
18
Is it possible to predict underestimation in ductal carcinoma in situ of the breast? Yes, using a simple score! ( 30665684 )
2019
19
A single-center study on total mastectomy versus skin-sparing mastectomy in case of pure ductal carcinoma in situ of the breast. ( 30683448 )
2019
20
Accuracy of Breast MRI Compared to MG in the Preoperative Detection and Measurement of Pure Ductal Carcinoma In Situ: A Methodological Issue. ( 30711410 )
2019
21
Qualitative Radiogenomics: Association Between BI-RADS Calcification Descriptors and Recurrence Risk as Assessed by the Oncotype DX Ductal Carcinoma In Situ Score. ( 30714832 )
2019
22
Behaviour and characteristics of low-grade ductal carcinoma in situ of the breast: literature review and single centre retrospective series. ( 30734334 )
2019
23
Response to: Accuracy of Breast MRI Compared to MG in the Preoperative Detection and Measurement of Pure Ductal Carcinoma In Situ: A Methodological Issue. ( 30737077 )
2019
24
Evaluating the relationship between ductal carcinoma in situ, calcifications, and margin status in patients undergoing breast conserving surgery. ( 30742316 )
2019
25
Ductal carcinoma in situ of the breast: an update for the pathologist in the era of individualized risk assessment and tailored therapies. ( 30760859 )
2019
26
An Uncommon Pairing of common Tumors: Case Report of Ductal Carcinoma in situ Within Fibroadenoma. ( 30766763 )
2019
27
Twenty-Five Year Trends in the Incidence of Ductal Carcinoma in Situ in US Women. ( 30772444 )
2019
28
Sentinel lymph node biopsy in microinvasive ductal carcinoma in situ. ( 30791092 )
2019
29
Magnetic resonance imaging of the breast: role in the evaluation of ductal carcinoma in situ. ( 30804615 )
2019
30
Preoperative Breast Magnetic Resonance Imaging in Women With Local Ductal Carcinoma in Situ to Optimize Surgical Outcomes: Results From the Randomized Phase III Trial IRCIS. ( 30811290 )
2019
31
Impact of Epithelial-Stromal Interactions on Peritumoral Fibroblasts in Ductal Carcinoma in Situ. ( 30816935 )
2019
32
Management of Ductal Carcinoma In Situ (DCIS) of the Breast: Present Approaches and Future Directions. ( 30834994 )
2019
33
Effect of preoperative injection of superparamagnetic iron oxide particles on rates of sentinel lymph node dissection in women undergoing surgery for ductal carcinoma in situ (SentiNot study). ( 30839104 )
2019
34
Accuracy of Distinguishing Atypical Ductal Hyperplasia From Ductal Carcinoma In Situ With Convolutional Neural Network-Based Machine Learning Approach Using Mammographic Image Data. ( 30860901 )
2019
35
The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). ( 30862637 )
2019
36
Surgery and adjuvant radiotherapy for unilateral ductal carcinoma in situ (DCIS) in women aged over 70 years: A population based cohort study. ( 30878169 )
2019
37
Granulomatous lobular mastitis associated with ductal carcinoma in situ of the breast. ( 30899513 )
2019
38
Genomic Assays to Assess Local Recurrence Risk and Predict Radiation Therapy Benefit in Patients With Ductal Carcinoma In Situ. ( 30900551 )
2019
39
Sentinel node mapping and ductal carcinoma in situ. ( 30903404 )
2019
40
AKT1low quiescent cancer cells in ductal carcinoma in situ of the breast. ( 30911675 )
2019
41
Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing. ( 30284611 )
2019
42
Comparison of Clinical and Pathologic Characteristics of Ductal Carcinoma in Situ Detected on Mammography versus Ultrasound Only in Asymptomatic Patients. ( 30322671 )
2019
43
Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ. ( 30362065 )
2019
44
Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up. ( 30894273 )
2019
45
Pathologic characterization of Felis catus papillomavirus type 5 (FcaPV-5)-associated viral plaques and Bowenoid in situ carcinoma in a Domestic Shorthair cat. ( 30905908 )
2019
46
Squamous Cell Carcinoma In Situ With Occult Invasion: A Tertiary Care Institutional Experience. ( 30893175 )
2019
47
A patient with squamous cell carcinoma in-situ successfully treated with intralesional 5-Fluorouracil and topical trichloroacetic acid. ( 30843746 )
2019
48
Detection of high-grade dysplasia, carcinoma in situ and squamous cell carcinoma in the upper aerodigestive tract: Recommendations for optimal use and interpretation of narrow-band imaging. ( 30222908 )
2019
49
Assessment of intraductal carcinoma in situ (DCIS) using grating-based X-ray phase-contrast CT at conventional X-ray sources: An experimental ex-vivo study. ( 30625220 )
2019
50
Trends in lobular carcinoma in situ management: endocrine therapy use in California and New Jersey. ( 30656538 )
2019

Variations for in Situ Carcinoma

Expression for in Situ Carcinoma

Search GEO for disease gene expression data for in Situ Carcinoma.

Pathways for in Situ Carcinoma

Pathways related to in Situ Carcinoma according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.72 BRCA1 CDKN2A EGFR ERBB2 ESR1 NR3C1
2
Show member pathways
12.88 EGFR ESR1 FKBP4 KRT14 KRT17 PGR
3
Show member pathways
12.76 CDH1 CDKN2A EGFR ERBB2 TP53
4 12.64 AGTR1 CDH1 CDKN2A EGFR ERBB2 ESR1
5
Show member pathways
12.46 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
6
Show member pathways
12.38 ERBB2 ESR1 NR3C1 PPIA
7 12.37 BRCA1 CDKN2A EGFR ERBB2 TP53
8
Show member pathways
12.22 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
9 12.16 EGFR ERBB2 ESR1 TP53
10
Show member pathways
12.08 EGFR ERBB2 ITGB4 TP53
11
Show member pathways
12.08 BRCA1 CDKN2A ESR1 NR3C1 PGR
12 11.99 BRCA1 CDH1 EGFR ESR1 TP53
13 11.98 EGFR ERBB2 ITGB4 TP53
14
Show member pathways
11.81 EGFR ERBB2 ESR1 PGR
15
Show member pathways
11.77 EGFR ERBB2 ESR1
16 11.75 BRCA1 EGFR FKBP4
17
Show member pathways
11.74 ESR1 NR3C1 PGR
18 11.62 CDH1 EGFR ERBB2
19 11.62 BRCA1 CDKN2A ERBB2 TP53
20 11.57 BRCA1 ERBB2 TP53
21 11.56 EGFR ERBB2 TP53
22 11.51 BRCA1 ERBB2 ITGB4
23 11.42 CDH1 CDKN2A EGFR ERBB2 TP53
24 11.39 CDKN2A EGFR TP53
25 11.05 CDH1 EGFR ERBB2 ITGB4
26 11.01 FKBP4 KRT14 KRT17 KRT5 NR3C1 TP53
27 10.59 FKBP4 NR3C1

GO Terms for in Situ Carcinoma

Cellular components related to in Situ Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.83 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
2 extracellular exosome GO:0070062 9.81 CDH1 FKBP4 ITGB4 KRT14 KRT17 KRT5
3 protein-containing complex GO:0032991 9.17 BRCA1 EGFR ESR1 FKBP4 NR3C1 PPIA
4 cytosol GO:0005829 10.03 CDKN2A ERBB2 ESR1 FKBP4 KRT14 KRT17

Biological processes related to in Situ Carcinoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.95 BRCA1 CDKN2A EGFR ESR1 NR3C1 PGR
2 regulation of apoptotic process GO:0042981 9.8 BRCA1 ESR1 PRDX2 TP53
3 positive regulation of cell growth GO:0030307 9.63 EGFR ERBB2 KRT17
4 positive regulation of transcription, DNA-templated GO:0045893 9.63 BRCA1 CDH1 CDKN2A EGFR ESR1 TP53
5 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.52 BRCA1 TP53
6 replicative senescence GO:0090399 9.51 CDKN2A TP53
7 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.48 ESR1 TP53
8 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.43 EGFR TP53
9 negative regulation of ERBB signaling pathway GO:1901185 9.37 EGFR ERBB2
10 cellular response to indole-3-methanol GO:0071681 9.32 BRCA1 CDH1
11 negative regulation of immature T cell proliferation in thymus GO:0033088 9.26 CDKN2A ERBB2
12 epidermis development GO:0008544 9.26 EGFR KRT14 KRT17 KRT5
13 hemidesmosome assembly GO:0031581 8.8 ITGB4 KRT14 KRT5

Molecular functions related to in Situ Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 AGTR1 BRCA1 CDH1 CDKN2A EGFR ERBB2
2 identical protein binding GO:0042802 9.87 BRCA1 CDH1 EGFR ERBB2 ESR1 PGR
3 protein kinase binding GO:0019901 9.83 CDKN2A EGFR ESR1 NR3C1 TP53
4 protein phosphatase binding GO:0019903 9.65 EGFR ERBB2 TP53
5 enzyme binding GO:0019899 9.65 BRCA1 EGFR ESR1 PGR TP53
6 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.58 EGFR ERBB2 ESR1
7 steroid hormone receptor activity GO:0003707 9.54 ESR1 NR3C1 PGR
8 nitric-oxide synthase regulator activity GO:0030235 9.46 EGFR ESR1
9 nuclear receptor activity GO:0004879 9.33 ESR1 NR3C1 PGR
10 steroid binding GO:0005496 8.8 ESR1 NR3C1 PGR

Sources for in Situ Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....